Psicologia

The new england
journal of medicine
established in 1812 june 26, 2008 vol. 358 no. 26
Rivaroxaban versus Enoxaparin for Thromboprophylaxis
after Hip Arthroplasty
Bengt I. Eriksson, M.D., Ph.D.,Lars C. Borris, M.D., Richard J. Friedman, M.D., Sylvia Haas, M.D.,
Menno V. Huisman, M.D., Ph.D., Ajay K. Kakkar, M.D., Ph.D., Tiemo J. Bandel, M.D., Horst Beckmann, Ph.D.,
Eva Muehlhofer, M.D.,Frank Misselwitz, M.D., Ph.D., and William Geerts, M.D., for the RECORD1 Study Group*
Abstr act
From Sahlgrenska University Hospital–
Östra, Gothenburg, Sweden (B.I.E.); Aarhus
University Hospital,Aarhus, Denmark
(L.C.B.); Medical University of South Carolina,
Charleston (R.J.F.); Institute of Experimental
Oncology and Therapy Research,
Technical University of Munich,
Munich, Germany(S.H.); Leiden University
Medical Center, Leiden, the Netherlands
(M.V.H.); Thrombosis Research Institute,
and Barts and the London School
of Medicine, London (A.K.K.); Bayer
HealthCare, Wuppertal,Germany (T.J.B.,
H.B., E.M., F.M.); and University of Toronto,
Toronto (W.G.). Address reprint requests
to Dr. Eriksson at the Orthopedic
Department, Sahlgrenska University Hospital–
Östra,Smorslottsgatan 1, SE-41685
Gothenburg, Sweden, or at b.eriksson@
orthop.gu.se.
*Members of the Regulation of Coagulation
in Orthopedic Surgery to Prevent
Deep Venous Thrombosis and Pulmonary
Embolism1 (RECORD1) Study Group
are listed in the Appendix.
N Engl J Med 2008;358:2765-75.
Copyright © 2008 Massachusetts Medical Society.
Background
This phase 3 trial compared the efficacy and safetyof rivaroxaban, an oral direct
inhibitor of factor Xa, with those of enoxaparin for extended thromboprophylaxis in
patients undergoing total hip arthroplasty.
Methods
In this randomized,double-blind study, we assigned 4541 patients to receive either
10 mg of oral rivaroxaban once daily, beginning after surgery, or 40 mg of enoxaparin
subcutaneously once daily, beginning the evening before...